Sera Prognostics Sets Stage for Commercial Success with Strong 2025 Performance
Sera Prognostics, a leading biotech company focused on preventing preterm birth, has made significant strides in advancing its commercial infrastructure and preparing for large-scale adoption of its innovative biomarker-based identification technology.
According to the company's Q4 2025 financial results conference call transcript reported on March 18, 2026, Sera Prognostics' President and CEO Zhenya Lindgardt highlighted that 2025 was a critical year for the company, marking significant progress in building evidence, access, and commercial infrastructure required to drive preterm adoption at scale.
One of the key milestones achieved by the company was the publication of its pivotal PRIME study in the Pregnancy journal of the Society for Maternal-Fetal Medicine. The study reported impressive results, showing a 56% and 32% reduction in babies born before 32 and 35 weeks of gestation, respectively.
The CEO noted that the full peer-reviewed publication of PRIME reinforces what Sera Prognostics has long believed: that biomarker-based identification of women at higher risk of preterm birth paired with a preventive treatment protocol can deliver meaningful reductions in preterm birth rates and drive improved health outcomes for babies.
Looking ahead to 2026, the company plans to extend this momentum through a thoughtful further analysis, publication, and real-world evidence generation strategy designed to communicate and replicate PRIME outcomes across diverse populations, geographies, and care models. These data will be essential as Sera Prognostics engages payers and broadens awareness across the clinical community.
Dr. Tiffany Inglis, Chief Medical Officer at Sera Prognostics, also spoke about the company's scientific and guideline engagement efforts, which are aimed at generating outcomes data that support both clinical adoption and reimbursement expansion.
A key part of this strategy has been launching targeted programs, particularly in Medicaid and high preterm birth burden states, to generate outcomes data that support clinical adoption and reimbursement expansion.
These efforts demonstrate Sera Prognostics' commitment to delivering meaningful reductions in preterm birth rates and driving improved health outcomes for babies. With its robust commercial infrastructure and innovative biomarker-based identification technology, the company is well-positioned for large-scale adoption and significant growth in 2026 and beyond.
As Sera Prognostics continues to make strides in advancing payer coverage and access, it is clear that this biotech company is on a path to commercial success. With its strong performance in 2025, the stage is set for a bright future ahead.
